Susquehanna International Group’s Taysha Gene Therapies TSHA Stock Holding History

Susquehanna International Group’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$526K	Buy	117,700 +60,500	+106%	+$281K	﹤0.01%	9539
2025 Q4	$315K	Sell	57,200 -4,600	-7%	-$22.3K	﹤0.01%	9834
2025 Q3	$202K	Sell	61,800 -31,500	-34%	-$89.2K	﹤0.01%	10967
2025 Q2	$216K	Buy	93,300 +28,800	+45%	+$62.6K	﹤0.01%	11060
2025 Q1	$89.7K	Buy	64,500 +18,300	+40%	+$30.6K	﹤0.01%	11605
2024 Q4	$79.9K	Buy	46,200 +30,700	+198%	+$63.7K	﹤0.01%	11470
2024 Q3	$31.2K	Sell	15,500 -34,000	-69%	-$74.6K	﹤0.01%	11528
2024 Q2	$111K	Buy	49,500 +22,000	+80%	+$64K	﹤0.01%	10951
2024 Q1	$78.9K	Sell	27,500 -7,600	-22%	-$15.8K	﹤0.01%	11345
2023 Q4	$62.1K	Sell	35,100 -50,200	-59%	-$100K	﹤0.01%	11619
2023 Q3	$270K	Buy	+85,300	New	+$159K	﹤0.01%	9589
2022 Q4	–	Sell	-15,600	Closed	-$30K	–	13702
2022 Q3	$30K	Buy	+15,600	New	+$56.6K	﹤0.01%	12448

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's TSHA Position: Q1 2026 in Review

Susquehanna International Group reduced its Taysha Gene Therapies (TSHA) stake by 6.9% in Q1 2026, selling an estimated $40.4K and leaving 116,297 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #9568.

Susquehanna International Group first reported a position in TSHA in Q2 2022 and has held it in 14 quarters since. The position peaked at $3.76M in Q1 2024. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Susquehanna International Group held 116,297 shares of Taysha Gene Therapies worth $520K as of Q1 2026.
Susquehanna International Group sold 8,678 Taysha Gene Therapies shares in Q1 2026, an estimated $40.4K.
Taysha Gene Therapies made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9568 holding.
Susquehanna International Group first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 14 quarters since.
Susquehanna International Group's Taysha Gene Therapies position peaked at $3.76M in Q1 2024.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.